Clinical Trial Update: A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome. [Phase 4]

View source ↗

Summary

Clinical trial investigating ruxolitinib and etoposide with the DDGP regimen for induction therapy in T/NK cell lymphoma-associated hemophagocytic syndrome (pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Syndrome
• Nk-cell Lymphoma

Drugs mentioned

• DDGP regimen
• Etoposide (Etoposide)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Zhengzhou University | Conditions: Hemophagocytic Syndrome, T/NK-Cell Lymphoma | Phase 4 | Status: UNKNOWN